Enrupatinib
CAS 2222689-47-4
MF C27H26N6O3 MW 482.5 g/mol
6-[3-methoxy-4-[(6-methyl-3-pyridinyl)methoxy]anilino]-3-morpholin-4-ylquinoxaline-5-carbonitrile
colony-stimulating factor 1 receptor (CSF1R) inhibitor, antineoplastic, EI 1071, EI-1071, 9L35RVQ9J6
ENRUPATINIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
EI-1071 is a selective Colony Stimulating Factor-1 Receptor kinase inhibitor.
- A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy VolunteersCTID: NCT04238364Phase: Phase 1Status: CompletedDate: 2025-02-25
- A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer’s Disease PatientsCTID: NCT06745583Phase: Phase 2Status: RecruitingDate: 2025-07-28
- OriginatorElixiron Immunotherapeutics
- Developer4B Technologies; Elixiron Immunotherapeutics
- ClassAntidementias; Antineoplastics; Small molecules
- Mechanism of ActionMacrophage colony-stimulating factor receptor antagonists
- Phase IIAlzheimer’s disease
- Phase IAmyotrophic lateral sclerosis; Giant cell tumour of tendon sheath
- No development reportedBreast cancer; Colorectal cancer
- 27 Jul 2025Pharmacodynamics data from preclinical studies in Alzheimer’s disease presented at the Alzheimer’s Association International Conference 2025 (AAIC-2025)
- 20 Dec 2024Phase-II clinical trials in Alzheimer’s disease (Treatment-experienced) in Taiwan (PO) (NCT06745583)
- 28 Jul 2024Adverse event data from a phase I trial in Alzheimer’s disease presented at the Alzheimer’s Association International Conference 2024 (AAIC-2024)
SYN
PAT
PAT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018071348&_cid=P12-MKLZ1L-03304-1
PAT
- Solid dispersion, pharmaceutical composition, and preparation method and use thereforPublication Number: WO-2025067450-A1Priority Date: 2023-09-28
- Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitorsPublication Number: WO-2025019622-A2Priority Date: 2023-07-18
- Quinoxaline compounds as type iii receptor tyrosine kinase inhibitorsPublication Number: US-2019308949-A1Priority Date: 2016-10-10
- Quinoxaline Compounds as Type III Receptor Tyrosine Kinase InhibitorsPublication Number: CN-110325515-APriority Date: 2016-10-10
- Quinoxaline compounds as type III receptor tyrosine kinase inhibitorsPublication Number: JP-7206188-B2Priority Date: 2016-10-10Grant Date: 2023-01-17
- quinoxaline compounds as type III tyrosine kinase receptor inhibitorsPublication Number: BR-112019007271-A2Priority Date: 2016-10-10
- Quinoxaline compounds as type III receptor tyrosine kinase inhibitorsPublication Number: AU-2017342928-A1Priority Date: 2016-10-10
- QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINKINASE INHIBITORSPublication Number: RU-2019113764-APriority Date: 2016-10-10
- Quinoxaline compounds as type iii receptor tyrosine receptor inhibitorsPublication Number: IL-265829-APriority Date: 2016-10-10
- Quinoxaline compounds as type iii receptor tyrosine kinase inhibitorsPublication Number: CA-3039919-A1Priority Date: 2016-10-10
- Quinoxaline compounds as type iii receptor tyrosine kinase inhibitorsPublication Number: WO-2018071348-A1Priority Date: 2016-10-10
- Quinoxaline compounds as inhibitors of type III receptor tyrosine kinasePublication Number: CN-110325515-BPriority Date: 2016-10-10Grant Date: 2023-06-20
- Quinoxaline compounds as type III receptor tyrosine kinase inhibitorsPublication Number: US-10689362-B2Priority Date: 2016-10-10Grant Date: 2020-06-23
AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
ADVERTISEMENT
ANAX LABORATORIES, WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
////////enrupatinib, ANAX, colony-stimulating factor 1 receptor (CSF1R) inhibitor, antineoplastic, EI 1071, EI-1071, 9L35RVQ9J6